First and only bladder cancer immunotherapy ‘TECENTRIQ’ acquires approval from MFDS
Roche Korea(GM Matt Sause) announced acquisition of approval of TECENTRIQ(atezolizumab), the first and only anti-PDL1 cancer immunotherapy, on the 12th of January as a secondary treatment from the Ministry of Food and Drug Safety(MFDS) for the treatment of people with locally advanced or metastat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
